Author Correction: Ablation of CD8α+ dendritic cell mediated cross-presentation does not impact atherosclerosis in hyperlipidemic mice (Scientific Reports, (2015), 5, 1, (15414), 10.1038/srep15414);Ablation of CD8α + dendritic cell mediated cross-presentation does not impact atherosclerosis in hyperlipidemic mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Legein, Bart ^a   Janssen, Edith M ^b   Theelen, Thomas L ^a   Gijbels, Marion J ^a,c   Walraven, Joep ^a   Klarquist, Jared S ^b   Hennies, Cassandra M ^b   Wouters, Kristiaan ^a   Seijkens, Tom T P ^c   Wijnands, Erwin ^a   Sluimer, Judith C ^a   Lutgens, Esther ^c,d   Zenke, Martin ^e   Hildner, Kai ^f   Biessen, Erik A L ^a   Temmerman, Lieve ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CD8 ANTIGEN; CD8 ANTIGEN, ALPHA CHAIN; EPITOPE; LOW DENSITY LIPOPROTEIN RECEPTOR; REPRESSOR PROTEIN; SNFT PROTEIN, MOUSE;

ANIMAL; ANTIGEN PRESENTATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW CELL; DENDRITIC CELL; GENETICS; HUMAN; HYPERLIPIDEMIA; IMMUNOLOGY; LYMPH NODE; MOUSE; PATHOLOGY; SPLEEN; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD8; ATHEROSCLEROSIS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BONE MARROW CELLS; DENDRITIC CELLS; EPITOPES; HUMANS; HYPERLIPIDEMIAS; LYMPH NODES; MICE; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL; REPRESSOR PROTEINS; SPLEEN; T-LYMPHOCYTES;

EID: 84944903026     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-020-65653-2     Document Type: Erratum

References (60)

1. Hansson, G. K., Libby, P. The immune response in atherosclerosis: a double-edged sword. Nature reviews. Immunology 6, 508-519, doi: 10.1038/nri1882 (2006).
2. Galkina, E., Ley, K. Immune and inflammatory mechanisms of atherosclerosis (∗). Annual review of immunology 27, 165-197, doi: 10.1146/annurev.immunol.021908.132620 (2009).
3. Sancho, D. et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458, 899-903, doi: 10.1038/nature07750 (2009).
4. Sancho, D. et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. The Journal of clinical investigation 118, 2098-2110, doi: 10.1172/JCI34584 (2008).
5. Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not crossreact in the cytotoxic assay. The Journal of experimental medicine 143, 1283-1288 (1976).
6. Shortman, K., Heath, W. R. The CD8+ dendritic cell subset. Immunological reviews 234, 18-31, doi: 10.1111/j.0105-2896.2009.00870.x (2010).
7. van der Aa, E., van Montfoort, N., Woltman, A. M. BDCA3CLEC9A human dendritic cell function and development. Seminars in cell & developmental biology, doi: 10.1016/j.semcdb.2014.05.016 (2014).
8. Villadangos, J. A., Shortman, K. Found in translation: the human equivalent of mouse CD8+ dendritic cells. The Journal of experimental medicine 207, 1131-1134, doi: 10.1084/jem.20100985 (2010).
9. Poulin, L. F. et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. The Journal of experimental medicine 207, 1261-1271, doi: 10.1084/jem.20092618 (2010).
10. Jongbloed, S. L. et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that crosspresents necrotic cell antigens. The Journal of experimental medicine 207, 1247-1260, doi: 10.1084/jem.20092140 (2010).
11. Bachem, A. et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+ CD141+ cells as homologues of mouse CD8+ dendritic cells. The Journal of experimental medicine 207, 1273-1281, doi: 10.1084/jem.20100348 (2010).
12. Crozat, K. et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. The Journal of experimental medicine 207, 1283-1292, doi: 10.1084/jem.20100223 (2010).
13. Niessner, A., Weyand, C. M. Dendritic cells in atherosclerotic disease. Clinical immunology 134, 25-32, doi: 10.1016/j. clim.2009.05.006 (2010).
14. Roselaar, S. E., Kakkanathu, P. X., Daugherty, A. Lymphocyte populations in atherosclerotic lesions of apoE and LDL receptor mice. Decreasing density with disease progression. Arteriosclerosis, thrombosis, and vascular biology 16, 1013-1018 (1996).
15. Zhou, X., Stemme, S., Hansson, G. K. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. The American journal of pathology 149, 359-366 (1996).
16. Yilmaz, A. et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 176, 101-110, doi: 10.1016/j.atherosclerosis.2004.04.027 (2004).
17. Gewaltig, J., Kummer, M., Koella, C., Cathomas, G., Biedermann, B. C. Requirements for CD8 T-cell migration into the human arterial wall. Human pathology 39, 1756-1762, doi: 10.1016/j.humpath.2008.04.018 (2008).
18. Grivel, J. C. et al. Activation of T lymphocytes in atherosclerotic plaques. Arteriosclerosis, thrombosis, and vascular biology 31, 2929-2937, doi: 10.1161/ATVBAHA.111.237081 (2011).
19. Stemme, S. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 92, 3893-3897 (1995).
20. Ahrens, S. et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 36, 635-645, doi: 10.1016/j.immuni.2012.03.008 (2012).
21. Profumo, E. et al. Actin is a target of T-cell reactivity in patients with advanced carotid atherosclerotic plaques. Mediators of inflammation 2013, 261054, doi: 10.1155/2013/261054 (2013).
22. Kyaw, T. et al. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 127, 1028-1039, doi: 10.1161/CIRCULATIONAHA.112.001347 (2013).
23. Elhage, R. et al. Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. The American journal of pathology 165, 2013-2018 (2004).
24. Kolbus, D. et al. TAP1-deficiency does not alter atherosclerosis development in Apoe?/? mice. PloS one 7, e33932, doi: 10.1371/journal.pone.0033932 (2012).
25. Fyfe, A. I., Qiao, J. H., Lusis, A. J. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. The Journal of clinical investigation 94, 2516-2520, doi: 10.1172/JCI117622 (1994).
26. Choi, J. H. et al. Flt3 signaling-dependent dendritic cells protect against atherosclerosis. Immunity 35, 819-831, doi: 10.1016/j. immuni.2011.09.014 (2011).
27. Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097-1100, doi: 10.1126/science.1164206 (2008).
28. Edelson, B. T. et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. The Journal of experimental medicine 207, 823-836, doi: 10.1084/jem.20091627 (2010).
29. Poulin, L. F. et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 119, 6052-6062, doi: 10.1182/blood-2012-01-406967 (2012).
30. Bougneres, L. et al. A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells. Immunity 31, 232-244, doi: 10.1016/j.immuni.2009.06.022 (2009).
31. Zelenay, S. et al. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. The Journal of clinical investigation 122, 1615-1627, doi: 10.1172/JCI60644 (2012).
32. Raghavan, M., Del Cid, N., Rizvi, S. M., Peters, L. R. MHC class I assembly: out and about. Trends in immunology 29, 436-443, doi: 10.1016/j.it.2008.06.004 (2008).
33. Ehst, B. D., Ingulli, E., Jenkins, M. K. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 3, 1355-1362 (2003).
34. Katz, J. D., Ondr, J. K., Opoka, R. J., Garcia, Z., Janssen, E. M. Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes. Journal of immunology 185, 1999-2003, doi: 10.4049/jimmunol.1001398 (2010).
35. Di Pucchio, T. et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nature immunology 9, 551-557, doi: 10.1038/ni.1602 (2008).
36. Asano, K. et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34, 85-95, doi: 10.1016/j.immuni.2010.12.011 (2011).
37. Packard, R. R. et al. CD11c(+ ) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+ ) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circulation research 103, 965-973, doi: 10.1161/CIRCRESAHA.108.185793 (2008).
38. Koltsova, E. K. et al. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. The Journal of clinical investigation 122, 3114-3126, doi: 10.1172/JCI61758 (2012).
39. Neuenhahn, M., Busch, D. H. Unique functions of splenic CD8alpha+ dendritic cells during infection with intracellular pathogens. Immunology letters 114, 66-72, doi: 10.1016/j.imlet.2007.09.007 (2007).
40. Tussiwand, R. et al. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 490, 502-507, doi: 10.1038/nature11531 (2012).
41. Seillet, C. et al. CD8alpha+ DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3. Blood 121, 1574-1583, doi: 10.1182/blood-2012-07-445650 (2013).
42. Ljunggren, H. G., Glas, R., Sandberg, J. K., Karre, K. Reactivity and specificity of CD8+ T cells in mice with defects in the MHC class I antigen-presenting pathway. Immunological reviews 151, 123-148 (1996).
43. Schaible, U. E., Collins, H. L., Priem, F., Kaufmann, S. H. Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. The Journal of experimental medicine 196, 1507-1513 (2002).
44. Araujo, J. A. et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Arteriosclerosis, thrombosis, and vascular biology 15, 1172-1180 (1995).
45. Mackarehtschian, K. et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3, 147-161 (1995).
46. McKenna, H. J. et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95, 3489-3497 (2000).
47. Daissormont, I. T. et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circulation research 109, 1387-1395, doi: 10.1161/CIRCRESAHA.111.256529 (2011).
48. Doring, Y. et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 125, 1673-1683, doi: 10.1161/CIRCULATIONAHA.111.046755 (2012).
49. Miyake, Y. et al. Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cellassociated antigens. The Journal of clinical investigation 117, 2268-2278, doi: 10.1172/JCI31990 (2007).
50. Torti, N., Walton, S. M., Murphy, K. M., Oxenius, A. Batf3 transcription factor-dependent DC subsets in murine CMV infection: differential impact on T-cell priming and memory inflation. European journal of immunology 41, 2612-2618, doi: 10.1002/eji.201041075 (2011).
51. Buckwalter, M. R., Srivastava, P. K. Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells. Cancer immunity 13, 2 (2013).
52. Luckashenak, N. et al. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 28, 521-532, doi: 10.1016/j.immuni.2008.02.018 (2008).
53. Steinman, R. M., Hawiger, D., Nussenzweig, M. C. Tolerogenic dendritic cells. Annual review of immunology 21, 685-711, doi: 10.1146/annurev.immunol.21.120601.141040 (2003).
54. Hermansson, A. et al. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 123, 1083-1091, doi: 10.1161/CIRCULATIONAHA.110.973222 (2011).
55. Habets, K. L. et al. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovascular research 85, 622-630, doi: 10.1093/cvr/cvp338 (2010).
56. Buono, C. et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proceedings of the National Academy of Sciences of the United States of America 102, 1596-1601, doi: 10.1073/pnas.0409015102 (2005).
57. Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., Schwartz, S. M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arteriosclerosis, thrombosis, and vascular biology 20, 1262-1275 (2000).
58. Sambrook, J., Fritsch, E., Maniatis, T. Molecular cloning: a laboratory manual. Vol. 2 (Cold Spring Harbor Laboratory Press, 1989).
59. Marsch, E. et al. Reversal of hypoxia in murine atherosclerosis prevents necrotic core expansion by enhancing efferocytosis. Arteriosclerosis, thrombosis, and vascular biology 34, 2545-2553, doi: 10.1161/ATVBAHA.114.304023 (2014).
60. Lutgens, E. et al. Requirement for CD154 in the progression of atherosclerosis. Nature medicine 5, 1313-1316, doi: 10.1038/15271 (1999).